DexCom stock (NASDAQ: DXCM) has seen a 17% fall in a month, compared to a 2% fall for the broader S&P500 index. This underperformance can be attributed to the reduced risk of cardiovascular events for obesity drugs of Novo Nordisk and likely Eli Lilly. Investors are concernDexCom stock (NASDAQ: DXCM) has seen a 17% fall in a month, compared to a 2% fall for the broader S&P500 index. This underperformance can be attributed to the reduced risk of cardiovascular events for obesity drugs of Novo Nordisk and likely Eli Lilly. Investors are concern
